Is Vertex Pharmaceuticals Stock a Buy?
Vertex Pharmaceuticals (NASDAQ: VRTX) is rapidly revolutionizing the treatment of cystic fibrosis, a devastating genetic condition that inhibits the lungs' ability to breathe and causes infections. More than 70,000 people worldwide have cystic fibrosis. There is currently no cure for the disease.
Vertex has developed the only four drugs globally that directly target the gene mutations behind the condition. The best among them, Trikafta, is actually a triple-combination therapy consisting of the other three, and it can treat more than 90% of cystic fibrosis patients. Is Vertex a buy on its ability to treat rare conditions and reward shareholders? Let's find out.
Image source: Getty Images.
Source Fool.com
